

enGene, Inc. Adds Leading Nanomedicine Expert To Scientific Advisory Board

VANCOUVER, BRITISH COLUMBIA (31 August 2010) enGene Inc., a biotechnology company developing a nucleotide (DNA or siRNA) delivery technology targeting mucosal tissues for treating a variety of diseases, including inflammatory bowel disease (IBD) and diabetes, announced today that Dr. Russell J. Mumper has joined the Company's Scientific Advisory Board.

Dr. Mumper is an internationally recognized leader in developing nanotechnologies for drug delivery. He is currently the Executive Associate Dean for Academics and the John A. McNeill Distinguished Professor at the UNC Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill. He also serves as the Director of the Center for Nanotechnology in Drug Delivery at UNC. Dr. Mumper has contributed extensively to the fields of nano-scale drug delivery systems, drug-polymer conjugates, and trans-mucosal drug and vaccine delivery. He has received over \$14 million in research grants and contracts, authored more than 215 scientific publications/abstracts and holds 38 granted and pending patents. Notably, Dr. Mumper was the first scientist to demonstrate the use of chitosan as a carrier for nucleotides and holds the earliest patent in this field.

"I'm impressed by the *in vivo* efficacy of the nucleotide delivery system developed by enGene's scientists and the potential of the technology to address critical unmet needs in medicine" says Dr. Mumper.

"We are very pleased to have Dr. Mumper join our Scientific Advisory Board. He brings to enGene a wealth of knowledge and expertise in formulation of nanoparticles for pharmaceutical applications, drug development and large-scale cGMP manufacturing of nanoparticles," says Anthony T. Cheung, enGene's Chief Scientific Officer. "Dr. Mumper's in-depth expertise in trans-mucosal drug delivery and the formulation and engineering of nanoparticles will be extremely relevant to enGene's current research direction, as we embark on developing an oral formulation for our nucleotide delivery system. We look forward to his strategic contribution to our research and development programs."

More about enGene

enGene Inc. has developed a highly flexible, biopolymer-based nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The two lead programs are delivery of an anti-inflammatory cytokine, IL-10, for treating Inflammatory Bowel Disease and delivery of insulin in a physiologic, meal-dependent fashion to regulate blood glucose levels. For more information please visit www.engeneinc.com.